PACAP for Retinal Health: Model for Cellular Aging and Rescue.
PACAP
aging
cell density
peptidergic pathways
retina
somatostatin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
17
12
2020
revised:
29
12
2020
accepted:
29
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
7
4
2021
Statut:
epublish
Résumé
Retinal aging is the result of accumulating molecular and cellular damage with a manifest decline in visual functions. Somatostatin (SST) and pituitary adenylate cyclase-activating polypeptide (PACAP) have been implicated in neuroprotection through regulating disparate aspects of neuronal activity (survival, proliferation and renewal). The aim of the present study was to validate a transgenic model for SST-expressing amacrine cells and to investigate the chronic effect of PACAP on the aging of SSTergic and dopaminergic cells of the retina. SST-tdTomato transgenic mice that were 6, 12 and 18 months old were treated intravitreally with 100 pmol of PACAP every 3 months. The density of SST and dopaminergic amacrine cells was assessed in whole-mounted retinas. Cells displaying the transgenic red fluorescence were identified as SST-immunopositive amacrine cells. By comparing the three age groups. PACAP treatment was shown to induce a moderate elevation of cell densities in both the SST and dopaminergic cell populations in the 12- and 18-month-old animals. By contrast, the control untreated and saline-treated retinas showed a minor cell loss. In conclusion, we report a reliable transgenic model for examining SSTergic amacrine cells. The fundamental novelty of this study is that PACAP could increase the cell density in matured retinal tissue, anticipating new therapeutic potential in age-related pathological processes.
Identifiants
pubmed: 33466261
pii: ijms22010444
doi: 10.3390/ijms22010444
pmc: PMC7796228
pii:
doi:
Substances chimiques
Pituitary Adenylate Cyclase-Activating Polypeptide
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Eur J Endocrinol. 2000 Oct;143 Suppl 1:S43-51
pubmed: 11068939
Nat Genet. 2002 May;31(1):47-54
pubmed: 11967539
Brain Res. 1990 Sep 10;527(1):21-31
pubmed: 1980839
Diabetes Care. 2005 Aug;28(8):1941-7
pubmed: 16043736
J Neurochem. 2011 Aug;118(3):365-78
pubmed: 21623792
J Pathol. 2018 Aug;245(4):478-490
pubmed: 29774542
Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H448-H462
pubmed: 29750567
Invest Ophthalmol Vis Sci. 1992 Jan;33(1):1-17
pubmed: 1730530
Histol Histopathol. 2003 Oct;18(4):1219-42
pubmed: 12973690
Pharmacol Rev. 2018 Oct;70(4):763-835
pubmed: 30232095
Front Neuroendocrinol. 1995 Jan;16(1):53-88
pubmed: 7768322
Science. 1999 Dec 17;286(5448):2358-61
pubmed: 10600750
Brain Res. 2002 May 17;936(1-2):1-14
pubmed: 11988224
Gen Comp Endocrinol. 2007 Aug-Sep;153(1-3):108-14
pubmed: 17289046
Brain Res. 1984 May 28;301(1):192-7
pubmed: 6145503
Eur J Med Res. 1997 Oct 30;2(10):441-4
pubmed: 9348272
J Neurochem. 2004 Jun;89(5):1057-91
pubmed: 15147500
J Mol Neurosci. 2019 Jul;68(3):475-484
pubmed: 30993644
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Mol Biosyst. 2014 Jun;10(6):1290-304
pubmed: 24514073
Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):267-75
pubmed: 16741711
Science. 2000 Mar 17;287(5460):2032-6
pubmed: 10720333
Nat Neurosci. 2007 Nov;10(11):1387-94
pubmed: 17965659
Antioxid Redox Signal. 2018 Jul 20;29(3):257-274
pubmed: 28891325
J Neurosci. 2011 Nov 2;31(44):16033-44
pubmed: 22049445
Mol Vis. 2016 Dec 30;22:1522-1531
pubmed: 28050125
Biochem Biophys Res Commun. 1989 Oct 16;164(1):567-74
pubmed: 2803320
Ann N Y Acad Sci. 2000;921:317-20
pubmed: 11193843
Pharmacol Rev. 2000 Jun;52(2):269-324
pubmed: 10835102
Front Immunol. 2019 Aug 20;10:1975
pubmed: 31481963
J Neurochem. 1999 Nov;73(5):1836-42
pubmed: 10537041
Histochemistry. 1982;76(2):137-52
pubmed: 6131054
Dev Biol. 2000 Apr 15;220(2):197-210
pubmed: 10753510
Proc Natl Acad Sci U S A. 1979 Jun;76(6):3019-23
pubmed: 288084
Peptides. 2007 Sep;28(9):1631-9
pubmed: 17574305
Horm Metab Res. 1979 Jan;11(1):79-80
pubmed: 428915
J Neurochem. 1997 Sep;69(3):1213-8
pubmed: 9282945
Brain Res. 1980 Oct 20;199(2):488-92
pubmed: 6106523
Front Neurosci. 2019 Oct 09;13:1031
pubmed: 31649495
Diabetes Care. 2002 Dec;25(12):2282-6
pubmed: 12453974
Diabetes. 2013 Jul;62(7):2569-78
pubmed: 23474487
Neuroscience. 2017 Apr 21;348:1-10
pubmed: 28215987
Geroscience. 2019 Dec;41(6):775-793
pubmed: 31655957
Pharmacol Rev. 2009 Sep;61(3):283-357
pubmed: 19805477
Br J Clin Pharmacol. 2013 May;75(5):1189-201
pubmed: 23043302
Cell Tissue Res. 1979;204(1):127-40
pubmed: 393400
Science. 1973 Jan 5;179(4068):77-9
pubmed: 4682131
Diabetes Care. 2007 Nov;30(11):2902-8
pubmed: 17704349
Arch Ital Biol. 2005 Sep;143(3-4):191-8
pubmed: 16097495
J Mol Neurosci. 2014 Nov;54(3):293-9
pubmed: 24723665
Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5266-75
pubmed: 17962482
Cell Tissue Res. 2012 Apr;348(1):37-46
pubmed: 22350850
Front Neurol. 2012 May 11;3:75
pubmed: 22593752
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3066-76
pubmed: 27286364
Vis Neurosci. 1996 Jul-Aug;13(4):721-33
pubmed: 8870228
N Engl J Med. 1998 Feb 26;338(9):624-6
pubmed: 9480445
Mol Cell Endocrinol. 2008 May 14;286(1-2):112-22
pubmed: 18242820
Trends Pharmacol Sci. 1995 Mar;16(3):86-8
pubmed: 7792934